Feeds:
Posts
Comments

The Puzzle of Stem Cells and Cancer Stem Cells: The MIT Stem Cell Initiative

January 13, 2019 by Irina Robu

The Puzzle of Stem Cells and Cancer Stem Cells: The MIT Stem Cell Initiative

Reporter: Irina Robu, PhD

The MIT Stem Cell Initiative is looking to research fundamental biological questions about normal adult stem cells and their malignant counterparts, cancer stem cells. The MIT Stem Cell Initiative is applying new technologies and approaches in pursuit of this goal. In particular, the MIT Stem Cell Initiative has focused on the breast and colon, as these tissues are quite different from each other, yet each constitutes a major portion of cancer occurrence. The program purposes are to

(a) identify the stem cells and cancer stem cells in various tissues and tumor types,

(b) control how these cells change during aging or with disease progression and

(c) determine the similarities and differences between

  • normal cells, and
  • cancer stem cells,

with the goal of finding weaknesses in cancer stem cells that can be feasible and exact targets for treatment.

In due course, the ability to identify, purify, and establish several populations of stem cells and cancer stem cells could aid researchers to understand the biology of these cells, and learn how to exploit them more efficiently in regenerative medicine applications and target them in cancer.

Normal adult stem cells are undifferentiated cells within a tissue that divide to produce two daughter cells and divide periodically to replenish or repair the tissue. One of the two daughter cells remain in the stem cell state and the other adopts a partially differentiated state, then goes on to divide and differentiate further to harvest multiple cell types that form that tissue. The division process is through a precise process to ensure that tissues are restricted to the appropriate size and cell content.

Cancer stem cells perform the same division but, rather than differentiating, the additional cells produced by the second daughter cell amass to form the bulk of the tumor.

  • Cancer stem cells can regrow the tumor, and
  • are frequently resistant to chemotherapy.

This exclusive ability of normal and cancer stem cells to both self-renew and form a tissue or tumor is referred to by researchers as “stemness,” and has important implications for biomedical applications.

As a result, cancer stem cells are thought to be responsible for

  • tumor recurrence after remission, and also for the
  • formation of metastases, which account for the majority of cancer-associated deaths.

Accordingly, an anti-cancer stem cell therapy that can target and kill cancer stem cells is one of the holy grail of cancer treatment as means to suppress both tumor recurrence and metastatic disease. One of the important tasks to studying normal and cancer stem cells, and to ultimately harnessing that knowledge is developing the ability to identify, purify, and propagate these cells. Accordingly, the main goal in stem cell and cancer stem cell research is discovering ways to distinguish them, preferably by identifying unique surface markers that can be used to cleanse stem cell and cancer stem cell populations and enable their study.

New technologies are permitting the researchers to make significant headway in these investigations, progress that was not possible just a few years ago. Explicitly, they are using

  • a mixture of specially cultured cells,
  • highly controllable mouse models of cancer, and s
  • ingle-cell RNA sequencing and
  • computational analysis techniques that are extremely matched to extracting an excessive deal of information from the moderately small number of stem cells.

SOURCE

http://news.mit.edu/2018/mit-initiative-delves-into-stem-cell-biology-1015

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Prevention: Research & Programs, Metastasis Process, Regenerative Biology and Medicine, stem cell biology and patient-specific | Tagged , , , | Leave a Comment »

Functioning Human Neural Networks Grown in 3D from Stem Cells

January 13, 2019 by Irina Robu

Functioning Human Neural Networks Grown in 3-D from Stem Cells

Reporter: Irina Robu, PhD

 

Researchers at Tuffs University developed three-dimensional human tissue model that mimics structural and functional features of the brain and were able to demonstrate sustained neural activity over several months. The 3D brain tissue models were the result of a collaborative effort between researchers from Tufts University School of Engineering, Tufts University School of Medicine, the Sackler School of Graduate Biomedical Sciences at Tufts, and the Jackson Laboratory.

 

These tissue models have the ability to populate a 3D matrix of silk protein and collagen with cells from patients with Parkinson’s disease, Alzheimer’s disease and the ability to

  • explore cell interactions,
  • disease progression and
  • response to treatment.

The 3D brain tissue models overcome a crucial challenge of previous models which is the availability of human source neurons due to the fact that neurological tissues are rarely removed from

  • healthy patients, and are usually available
  • post-mortem from diseased patients.

The 3D tissue models are populated with human induced pluripotent stem cells (iPSCs) that can be derived from several sources, including patient skin. The iPSCs are generated by turning back the clock on cell development to their embryonic-like precursors. They can then be dialed forward again to any cell type, including neurons. The porous structure of the 3D tissue cultures labeled in the research delivers sufficient oxygenation, access for nutrients and measurement of cellular properties. A clear window in the center of each 3D matrix allows researchers to visualize the

  • growth,
  • organization and
  • behavior of individual cells.

According to David L. Kaplan, “the silk-collagen scaffolds provide the right environment to produce cells with the genetic signatures and electrical signaling found in native neuronal tissues”. Compared to growing and culturing cells in two dimensions, the three-dimensional matrix yields a knowingly extra complete mix of cells found in neural tissue, with the appropriate morphology and expression of receptors and neurotransmitters. Other researchers have used iPSCs to create brain-like organoids, but can still make it difficult figuring out what individual cells are doing in real time. Likewise, cells in the center of the organoids may not obtain enough oxygen or nutrients to function in a native state.

However, the researchers can see a great advantage of the 3D tissue models with advanced imaging techniques, and the addition of cell types such as microglia and endothelial cells,to create a more complete model of the brain environment and the complex interactions that are involved in

  • signaling,
  • learning and plasticity, and
  • degeneration.

 

SOURCE

https://www.rdmag.com/news/2018/10/scientists-grow-functioning-human-neural-networks-3d-stem-cells

Posted in 3D Plotting Scaffolds, 3D Printing for Medical Application, BioPrinting in Regenerative Medicine, Stem Cells for Regenerative Medicine, Tissue Engineering, Tissue Engineering and Regenerative Medicine | Tagged , , , , | Leave a Comment »

Carbon Nano-tube Design Halts Dust Harmful Protective Gear

January 13, 2019 by Irina Robu

Carbon Nano-tube Design Halts Dust Harmful Protective Gear by Deterring Particles

Reporter: Irina Robu, PhD

A self-cleaning spacesuit was developed by engineers using carbon nanotube technology to purge itself from hyper-abrasive space dust. The sharp and sticky particles can cause noteworthy wear and tear on protective gear as well as causing them to overheat.Kavya Manyapu, a flight crew operations and test engineer for Starliner Spacecraft at Boeing, has now created a way to magnetize flexible carbon nanotube fibers which make the fabric immune to the problematic dust particles. A magnetic field induces a process known as electrophoresis, which carries and moves charged particles away from an area to stop it building up in certain areas.

However, particles on our moon and other planets are sharper and abrasive because of the atmosphere which erodes bulging edges here on Earth. It is also often electrically charged due to the relentless and unfiltered UV rays from space which experts say make the dust particles ‘sticky’. Static electricity aids the dust cling to a spacesuit and then wears out the fabric – often in crevices and folds such as elbows and knees.

Carbon nano-tubes are already in use to stop dust settling on solar panels and other sensors in space but they are brittle and ill-suited for use in clothing. However, scientists have found a way to make technology flexible with the use of small magnetic field created a fabric that can repel the dust.
Boeing engineers created a fully functioning knee joint section to prove their concept was operative. The segment was fully pressurized, as it would be on future lunar and Martian missions. It can even be adapted to improved suit the circumstances and requirements of other planets.

SOURCE

https://nano-magazine.com/news/2019/1/9/self-cleaning-spacesuits-could-help-astronauts-survive-on-mars

Posted in Materials Science & Engineering, Programmable Sensors (Carbon Nano Tubes) | Tagged , , , | Leave a Comment »

Changes in Levels of Sex Hormones and N-Terminal Pro–B-Type Natriuretic Peptide as Biomarker for Cardiovascular Diseases

January 13, 2019 by Dr. Sudipta Saha

Changes in Levels of Sex Hormones and N-Terminal Pro–B-Type Natriuretic Peptide as Biomarker for Cardiovascular Diseases

Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Considerable differences exist in the prevalence and manifestation of atherosclerotic cardiovascular disease (CVD) and heart failure (HF) between men and women. Premenopausal women have a lower risk of CVD and HF compared with men; however, this risk increases after menopause. Sex hormones, particularly androgens, are associated with CVD risk factors and events and have been postulated to mediate the observed sex differences in CVD.

 

B-type natriuretic peptides (BNPs) are secreted from cardiomyocytes in response to myocardial wall stress. BNP plays an important role in cardiovascular remodelling and volume homeostasis. It exerts numerous cardioprotective effects by promoting vasodilation, natriuresis, and ventricular relaxation and by antagonizing fibrosis and the effects of the renin-angiotensin-aldosterone system. Although the physiological role of BNP is cardioprotective, pathologically elevated N-terminal pro–BNP (NT-proBNP) levels are used clinically to indicate left ventricular hypertrophy, dysfunction, and myocardial ischemia. Higher NT-proBNP levels among individuals free of clinical CVD are associated with an increased risk of incident CVD, HF, and cardiovascular mortality.

 

BNP and NT-proBNP levels are higher in women than men in the general population. Several studies have proposed the use of sex- and age-specific reference ranges for BNP and NT-proBNP levels, in which reference limits are higher for women and older individuals. The etiology behind this sex difference has not been fully elucidated, but prior studies have demonstrated an association between sex hormones and NT-proBNP levels. Recent studies measuring endogenous sex hormones have suggested that androgens may play a larger role in BNP regulation by inhibiting its production.

 

Data were collected from a large, multiethnic community-based cohort of individuals free of CVD and HF at baseline to analyze both the cross-sectional and longitudinal associations between sex hormones [total testosterone (T), bioavailable T, freeT, dehydroepiandrosterone (DHEA), SHBG, and estradiol] and NT-proBNP, separately for women and men. It was found that a more androgenic pattern of sex hormones was independently associated with lower NT-proBNP levels in cross-sectional analyses in men and postmenopausal women.

 

This association may help explain sex differences in the distribution of NT-proBNP and may contribute to the NP deficiency in men relative to women. In longitudinal analyses, a more androgenic pattern of sex hormones was associated with a greater increase in NT-proBNP levels in both sexes, with a more robust association among women. This relationship may reflect a mechanism for the increased risk of CVD and HF seen in women after menopause.

 

Additional research is needed to further explore whether longitudinal changes in NT-proBNP levels seen in our study are correlated with longitudinal changes in sex hormones. The impact of menopause on changes in NT-proBNP levels over time should also be explored. Furthermore, future studies should aim to determine whether sex hormones directly play a role in biological pathways of BNP synthesis and clearance in a causal fashion. Lastly, the dual role of NTproBNP as both

  • a cardioprotective hormone and
  • a biomarker of CVD and HF, as well as
  • the role of sex hormones in delineating these processes,

should be further explored. This would provide a step toward improved clinical CVD risk stratification and prognostication based on

  • sex hormone and
  • NT-proBNP levels.

 

References:

 

https://www.medpagetoday.com/clinical-connection/cardio-endo/76480?xid=NL_CardioEndoConnection_2018-12-27

 

https://www.ncbi.nlm.nih.gov/pubmed/30137406

 

https://www.ncbi.nlm.nih.gov/pubmed/22064958

 

https://www.ncbi.nlm.nih.gov/pubmed/24036936

 

https://www.ncbi.nlm.nih.gov/pubmed/19854731

 

Posted in Acute Myocardial Infarction, Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias, Biomarkers & Medical Diagnostics, Cardiovascular Research, Clinical Diagnostics, congestive heart failure, Disease Biology, Endocrine Diseases, Heart and Brain Disease in Women, Proteomics, Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics | Tagged , , , , | Leave a Comment »

Information Innovation and the Power of LPBI Group

January 11, 2019 by Rick Mandahl

Information Innovation and the Power of LPBI Group

Author: Rick Mandahl, MBA

LPBI Group, Business Development Team

 

“Science evolves”[1]. This simple quote from a position paper by William S. Harten[2], eminent database architect, genealogist and entrepreneur describes why he designed a new laboratory process management technology capable of adapting as processes changed. From the notion that the software system must support the science rather than the science being bound to the limitations of predefined rigid systems opened new vistas for exploration, and progress across many process intensive domains and certainly in the realm precision medicine moving into widespread clinical deployment. Science evolves.

Decades earlier Robert R. Johnson, PhD[3] leader of the GE engineering team responsible for computerizing the check processing system for the Bank of America, and in the process delivered technology that changed banking globally.  The initial exploratory endeavor began around 1950 at Stanford Research Institute [aka, SRI International, Menlo Park, CA] to address the exponential expansion of check processing bound by manual methods, thus the need to change a system that was conceived in Venice in 1431, roughly the same era as the invention of the Gutenberg Press. In Project ERMA among other things, developed the human and machine readable alphanumerics still found on every check issued in the world today. The same information could be shared by humans and machines and this realtime translation, realtime information [4] that helped manage the exponential increase in demand for financial services in the post World War Two era.

Technology supporting science, supporting commerce in our era changes centuries established methods.  Do scientific publications today advance science or simply report it? Can we do better?  How far are we beyond Gutenberg today? In 1995, Nicholas Negroponte of MIT’s Media Lab lamented that the FAX machine was barely a step beyond Gutenberg.[5] In the ensuing generation has scientific publishing advanced with the science it reports? LPBI Group thinks not.

What of new innovation in the expanding realm of life sciences? Where are the friction points that may impede progress in rapidly advancing areas of medical sciences – science whose validation rests on rigorous observation and adherence to scientific method, findings vetted by peer review and shared in scholarly journals of learned societies. Are there ways to improve, approaches to help ameliorate the current concern over “research productivity”?

Personal Reflection of an Innovation Case Study

In the early eighties upon returning from a year’s assignment in  France, I looked up a former skiing and climbing partner now Head Coach of the US Ski Team. I had heard that he was working on a new design of racing bicycle handle bars – which from afar seemed quite curious. A visit to his home near Sun Valley  resulted in an astonishing perspective. In a field where just about every innovation had been made for this simple machine, the bicycle, Boone Lennon theorized that aerodynamic improvement – the way a rider sat on the bicycle could deliver improved performance – this insight gained by observing and coaching some of the best ski racers in the world on improving their aerodynamic form in the greatest of alpine ski sports – the Downhill. Those body position principles, so important to a sport where the difference between victory or defeat is measured in hundredths of a second – those principles ought to apply to bicycle racing where on straight away courses with “two equally matched and equipped competitors, the racer with the new bars and improved aerodynamic position will win.”[6] The theory was proven when in 1989 Greg Lemond the first American to win the Tour de France used the new “aero bars” . This second of three Tour de France victories (also 1986 and 1990), was attributed by Mr. Lemond to the final time trial where he outpaced his opponent by eight seconds, the tightest margin in Tour de France history. LeMond’s superior aerodynamics brought him victory[7] – he triumphed where two comparably qualified and equipped competitors had different tools that resulted in different levels of efficiency, thus performance. 

Winning Strategy in the Information Age

In the competitive world of scientific and medical research, where can efficiencies be gained, productivity be improved?

  • Containing Information Explosion,
  • Combatting Information Obsolescence.

The game changing innovations of LPBI Group offer simple yet profound innovations to help scientists and clinicians advance at the pace they can reasonably pursue because LPBI Group’s products help keep pace with life sciences new research insights and scientific discoveries. LPBI Group  ongoing questions provide answers using curation of current scientific research results. 

  • No longer are scientific papers obsolete by the time they are published, rather
  • They are living and dynamic repositories of searchable curated knowledge to build upon, while leveraging past established benchmarks.
  • Equally qualified and equipped, what investigator, which team might advance faster?
  • Access to the best and current information would certainly be of help.
  • Access absent enormous subscription cost might help as well.
  • Accelerate information access, eliminate exorbitant access cost.

The Founders, The Finders, The Funders. 

To build a team, to create a venture, to have commercial impact, the initial founder(s) must be joined by team members who help build, refine, adapt and change as the initial concept grows to advancing stages of maturity.

The time comes when the greatest intellectual and commercial impact is likely delivered by partners whose established business channels and financial strength enable the full realization of innovation or enabling technology far beyond the operational capacities of the initial team, but exactly according their ultimate vision.

Thus, as LPBI Group grows, we seek to identify and recruit strategic partners to grow, to expand and to merge with a new structure to follow. The global community of scientists indeed all the humankind are the beneficiaries of our endeavors in knowledge creation and dissemination.

[1] UNIFlow® by UNIConnect White Paper, William S. Harten

[2] Mr. Harten in addition to being founder of UNIConnect, LC, acquired by Sunquest Information Systems is inventor of GEDCOM, the global standard for the exchange of genealogical information.

[3] Robert Royce Johnson, PhD Cal Tech, Leader of Project ERMA, VP of Engineering Emeritus- Burroughs; Professor and Chairman Emeritus Dept of Computer Science, University of Utah College of Engineering. Founder and Managing Partner n-Dimensional Visualization, LLC.

[4] Waves of Change, James L McKenney, Harvard Business School, Harvard Business Press, 1995

[5] Being Digital, Nicholas Negroponte, MIT Medial Lab, Random House 1995

[6] Personal conversations with Daniel “Boone” Lennon, Head Coach Emeritus, US Ski Team and inventor of the Aero Bar for cyclists.

[7] Simon Symthe, “How Greg LeMond’s aero bars revolutionized time trialling”, Cycling, July 9, 2015.

Posted in Innovations, IP Development by LPBI Group Team, IP Development by LPBI Group Team & Other Organizations, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management | Leave a Comment »

LIVE 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, Friday, May 17, 2019 from 8:00 AM to 5:00 PM EDT

January 11, 2019 by 2012pharmaceutical

LIVE 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, Friday, May 17, 2019 from 8:00 AM to 5:00 PM EDT

 

Wasserstein Hall, Milstein West (2019)

Petrie-Flom Center

23 Everett St., Rm. 327

Cambridge, MA 02138

https://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference

This year’s conference is organized in collaboration with Nita A. Farahany, Duke Law School, and Henry T. Greely, Stanford Law School.

REAL TIME Press Coverage for http://pharmaceuticalintelligence.com 

by Aviva Lev-Ari, PhD, RN

Director & Founder, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief, Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com

Editor-in-Chief, BioMed e-Series, 16 Volumes in Medicine, https://pharmaceuticalintelligence.com/biomed-e-books/

 

@pharma_Bi

@AVIVA1950

 

Logo, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Our BioMed e-series

WE ARE ON AMAZON.COM

https://lnkd.in/ekWGNqA

  • Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics. On Amazon.com since 11/29/2015

http://www.amazon.com/dp/B018PNHJ84

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology – Work-in-Progress

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

 

 

2019 Petrie-Flom Center Annual Conference: Consuming Genetics:

Ethical and Legal Considerations of New Technologies

AGENDA NOW AVAILABLE! 2019 Petrie-Flom Center Annual Conference image

 May 17, 2019 8:30 AM – 5:15 PM
 Conferences
 2018-2019
Harvard Law School, Wasserstein Hall, Milstein West (2019)
1585 Massachusetts Ave., Cambridge, MA
Register for this event

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is pleased to announce plans for our 2019 annual conference: “Consuming Genetics: The Ethical and Legal Considerations of Consumer Genetic Technologies.” This year’s conference is organized in collaboration with Nita A. Farahany, Duke Law School, and Henry T. Greely, Stanford Law School.

 

Description

Breakthroughs in genetics have often raised complex ethical and legal questions, which loom ever larger as genetic testing is becoming more commonplace, affordable, and comprehensive and genetic editing becomes poised to be a consumer technology. As genetic technologies become more accessible to individuals, the ethical and legal questions around the consumer use of these technologies become more pressing.

Already the global genetic testing and consumer/wellness genomics market was valued at $2.24 billion in 2015 and is expected to double by 2025 to nearly $5 billion. The rise of direct-to-consumer genetic testing and DIY kits raise questions about the appropriate setting for these activities, including a concern that delivering health-related results directly to consumers might cause individuals to draw the wrong medical conclusions. At the same time, advances in CRISPR and other related technologies raise anxieties about the implications of editing our own DNA, especially as access to these technologies explode in the coming years.

In an age where serial killers are caught because their relatives chose to submit DNA to a consumer genealogy database, is genetic privacy for individuals possible? Does the aggregation of data from genetic testing turn people into products by commercializing their data? How might this data reduce or exacerbate already significant health care disparities? How can we prepare for widespread access to genetic editing tools?

As these questions become more pressing, now is the time to re-consider what ethical and regulatory safeguards should be implemented and discuss the many questions raised by advancements in consumer genetics.

This event is free and open to the public, but space is limited and registration is required. Register now!

#DTCgenome

@PetrieFlom

@pharma_BI

@AVIVA1950

Agenda

8:30 – 9:00am, Registration

A continental breakfast will be available.

9:00 – 9:10am, Welcome Remarks

9:10 – 10:10am, Consumer Genetic Technologies: Rights, Liabilities, and Other Obligations

  • Gary Marchant, Regent’s Professor, Sandra Day O’Connor College of Law and Director, Center for Law, Science, and Innovation, Arizona State University (with Mark Barnes, Ellen W. Clayton, and Susan M. Wolf) – Liability Implications of Direct-to-Consumer Genetic Testing
  1. Insurance may not cover BRCA genetic testing even for Patients with diagnosis of Breast cancer
  • Anya Prince, Associate Professor of Law, University of Iowa College of Law and Member of the University of Iowa Genetics Cluster – Consuming Genetics as an Insurance Consumer
  1. Life insurance company initiated genetic testing: (a) Gatekeeping policy underwriting new comer applicants (b) Wellness Employer wellness programs incentivize healthy behavior Incorporate genetic testing into wellness Programs Test for preventing genetic conditions Like BRCA, Lynch syndrome, preventable – win/win proposition –>>> Healthier employees. Studies show shift of cost from employer to employee and employer have access to genetic information of employees.
  • Life Insurance – JH Vitality program, get Apple watch if meet goals, premium is lower – incentive
  • DTC companies beginning to market to Insurance
  • Employment Legal Landscape:
  1. legal regulations
  • Jessica Roberts, Professor, Alumnae College Professor in Law, and Director of the Health Law & Policy Institute, University of Houston Law Center – In Favor of Genetic Conversion: An Argument for Genetic Property Rights
  1. Ownership right to Genetic Property rights of the Information, consented to transfer or abandonment
  2. Conversion – Informed consent
  3. Family not in treatment relationship with the Researcher – Court rejected the claim family donated to research unfair benefir of the Hospital from the data and tissue donated
  4. Claim of conversion – Common Law
  5. Gene by Gene Family Tree DNA
  6. Courts shows a newfound openness to claims for genetic conversion
  7. claims for genetic conversion will not stifle reaserch or create moral harms
  8. consumers genetics, claims for genetic conversion are actually necessary to adequately protect people’s interests in their DNA
  • Moderator: I. Glenn Cohen, Faculty Director and James A. Attwood and Leslie Williams Professor of Law

10:10 – 10:20am, Break

10:20 – 11:40am, Privacy in the Age of Consumer Genetics

  • Jorge Contreras, Professor, College Of Law and Adjunct Professor, Human Genetics, University of Utah – Direct to Consumer Genetics and Data Ownership
  • Seema Mohapatra, Associate Professor of Law, Indiana University Robert H. McKinney School of Law – Abolishing the Myth of “Anonymous” Gamete Donation in the Age of Direct-to-Consumer Genetic Testing
  • Kayte Spector-Bagdady, Assistant Professor, Department of Obstetrics and Gynecology and Chief, Research Ethics Service, Center for Bioethics and Social Sciences in Medicine (CBSSM), University of Michigan Medical School – Improving Commercial Health Data Sharing Policy: Transparency, Accountability, and Ethics for Academic Use of Private Health Data Resources
  • Liza Vertinsky, Associate Professor of Law, Emory University School of Law and Emory Global Health Institute Faculty Fellow (with Yaniv Heled) – Genetic Privacy and Public Figures
  • Moderator: Nita Farahany, Professor of Law and Professor of Philosophy, Duke Law School

11:40am – 12:40pm, Tinkering with Ourselves: The Law and Ethics of DIY Genomics

  • Barbara J. Evans, Mary Ann & Lawrence E. Faust Professor of Law and Director, Center on Biotechnology & Law, University of Houston Law Center; Professor, Electrical and Computer Engineering, Cullen College of Engineering, University of Houston – Programming Our Genomes, Programming Ourselves: The Moral and Regulatory Limits of Self-Harm When Consumers Wield Genomic Technologies
  • Maxwell J. Mehlman, Distinguished University Professor, Arthur E. Petersilge Professor of Law, and Director of the Law-Medicine Center, Case Western Reserve University School of Law, and Professor of Biomedical Ethics, Case Western Reserve University School of Medicine (with Ronald A. Conlon) – Governing Non-Traditional Biology
  • Patricia J. Zettler, Associate Professor, Center for Law Health and Society, Georgia State University College of Law (with Christi Guerrini and Jacob S. Sherkow) – Finding a Regulatory Balance for Genetic Biohacking
  • Moderator: Henry T. Greely, Director, Center for Law and the Biosciences; Professor (by courtesy) of Genetics, Stanford School of Medicine; Chair, Steering Committee of the Center for Biomedical Ethics; and Director, Stanford Program in Neuroscience and Society, Stanford University

12:40 – 1:20pm, Lunch

Lunch will be provided.

1:20 – 2:20pm, Regulating Consumer Genetic Technologies

  • James Hazel, postdoctoral fellow, Center for Genetic Privacy and Identity in Community Settings (GetPreCiSe), Vanderbilt University Medical Center – Privacy Best Practices for Consumer Genetic Testing Services: Are Industry Efforts at Self-Regulation Sufficient?
  • Scott Schweikart, Senior Research Associate, Council on Ethical and Judicial Affairs, American Medical Association and Legal Editor, AMA Journal of Ethics – Human Gene Editing: An Ethical Analysis and Arguments for Regulatory Guidance at Both the National and Global Levels
  • Catherine M. Sharkey, Crystal Eastman Professor of Law, NYU School of Law (with Kenneth Offit) – Regulatory Aspects of Direct-to-Consumer Genetic Testing: The Emerging Role of the FDA
  1. Genetic predisposition – BRCA I & II – approved Testing
  2. Pharmaco-genetic Test authorization – incorrect interpretation, incorrect action based on results
  3. Regulatory model, pathway
  4. False positive and False negative BRCA I & II
  5. 23&Me – huge DB, big data who controls the data
  6. Across regulatory – liability issues on who own big data
  • Moderator: Rina Spence, President of SpenceCare International LLC

2:20 – 2:30pm, Break

2:30 – 3:50pm, Consumer Genetics and Identity

  • Kif Augustine-Adams, Ivan Meitus Chair and Professor of Law, BYU Law School – Generational Failures of Law and Ethics: Rape, Mormon Orthodoxy, and the Revelatory Power of Ancestry DNA
  1. Complex Sorrows: Anscestry DNA – 20 Millions records. Complete anonymity and privacy collapsed
  • Jonathan Kahn, James E. Kelley Chair in Tort Law and Professor of Law, Mitchell-Hamline School of Law – Precision Medicine and the Resurgence of Race in Genomic Medicine
  1. precision medicine – classification of individuals into subpopulations that differ in their susceptability to a particular disease
  2. Blurring DIversity and Genetic Variation, Empirical and Normative Inclusion
  3. NHGRI – underrepresented of diversity in the community of genomics research professional is a socioeconomics issue not a genetics one – underrepresentation in DBs
  4. What does Diversity mean?
  5. Underrepresentation not race: Scientific workforce, recruitment sites recruitment cohort, Ancestry, Genetic variation, responsibilities for disparities
  6. Genetic Diversity rare alleles ->> actionable alleles
  • Emily Largent, Assistant Professor, Department of Medical Ethics and Health Policy and Senior Fellow, Leonard Davis Institute of Health Economics, University of Pennsylvania – Losing Our Minds? Direct-to-Consumer Genetic Testing and Alzheimer’s Disease
  1. Protect people and knowledge about one’s disease
  2. AD & APo-E Gene, e-2, e-3, e-4 – Carriers increase risk to AD too 40%
  • Natalie Ram, Assistant Professor of Law, University of Baltimore School of Law – Genetic Genealogy and the Problem of Familial Forensic Identification
  1. Opt in to share genetic data on the platforms opt in national DB
  2. Genetic relatedness is stickier than social relations
  3. Voluntary sharing of genetic information – no other party can protect genetic information of any person, thu, if shared voluntarily
  4. Geneology is involuntarily disclosure of genetic information
  5. Familial Forensic Identification – Privacy for information held by Telephone companies
  6. Involuntarily Identification by genomic and genetic data genetic markers
  • Moderator: Carmel Shachar, Executive Director, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics and Lecturer at Law, Harvard Law School
  1. Genetic relatedness

3:50 – 4:00pm, Break

4:00 – 5:00pm, The Impact of Genetic Information

  • Leila Jamal, Genetic Counselor, Division of Intramural Research and Co-Investigator, Centralized Sequencing Initiative, National Institute of Allergy and Infectious Diseases and Affiliated Scholar, Department of Bioethics, National Institutes of Health (with Benjamin Berkman and Will Schupmann) – An Ethical Framework for Genetic Counseling Practice in the Genomic Era
  1. Genetic Counseling – to benefit the patient, positive autonomy, benefiecence – how potentially impactful is the Test Information
  2. Nondirectiveness – Why?
  3. distance from eugenics + abortion politics
  4. persons ans patient autonomy – non-interference
  5. Genetic and Genomics Testing: Prenata, Pediatric, Vancer, other: Cardiology, Neurology, Hematology, Infectious diseases, pharmaco genomics, DTC, Ancestry
  6. Pre- Test Genetic Counseling – information and testing need, indication for testing
  7. Post-Test
  8. Informational Burden low vs high: Likely pathogenic, Pathogenic vs benign – natural history data
  9. potentially high impact – Testing that can reveal an action to be taken
  10. Relation with Patient close vs distant – recommendation based on best evidence +guidelines available
  11. Institutional role of Counselor
  • Emily Qian, Genetic Counselor, Veritas Genetics (with Magalie Leduc, Rebecca Hodges, Bryan Cosca, Ryan Durigan, Laurie McCright, Doug Flood, and Birgit Funke) – Physician-Mediated Elective Whole Genome Sequencing Tests: Impacts on Informed Consent
  1. DTC
  2. Physician-initiated Genetic Testing
  3. Physician-initiated DTC
  4. Informed consent is a process: Topics covered – possible results & consequences
  5. Health Care Provider (HCP) Demographics: Neurology
  6. Analysis: Family Name
  7. Informed consent – who is responsible
  8. Consumers
  • Vardit Ravitsky,@VarditRavitsky  Associate Professor, Bioethics Programs, Department of Social and Preventive Medicine, School of Public Health, University of Montreal; Director, Ethics and Health Branch, Center for Research on Ethics – Non-Invasive Prenatal Whole Genome Sequencing: Ethical and Regulatory Implications for Post-Birth Access to Information
  • Moderator: Melissa Uveges, Postdoctoral Fellow, Harvard Medical School Center for Bioethics
  1. Clear conceptual approach
  2. Prioritize privacy/open future banning NIPW vs right to know unrestricted NIPW, prioritizing parental autonomy ->> allowing restrictions to be built in

5:00 – 5:15pm, Closing Remarks

 

Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School with support from the Center for Bioethics at Harvard Medical School and the Oswald DeN. Cammann Fund at Harvard University.

SOURCE

http://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference

Posted in and Bioethics, Biotechnology, Conference Coverage with Social Media, Health Law Policy | Leave a Comment »

#JPM19: Health-Care CEOs Outline Strategies at J.P. Morgan Conference

January 10, 2019 by Gail S Thornton

Reporter: Gail S. Thornton

 

From The Wall Street Journal (www.wsj.com)

By Peter Loftus and Anna Wilde Mathews

Published January 9, 2019

Health-Care CEOs Outline Strategies at J.P. Morgan Conference

Chiefs at Johnson & Johnson, CVS discuss what’s next on a range of industry issues

One of the biggest health conferences of the year for investors, the J.P. Morgan Health-Care Conference, is taking place this week in San Francisco. Here are some of the hot topics covered at the four-day event, which wraps up Thursday.

BioMarin Mulls Payment Plans

BioMarin Pharmaceutical Inc. CEO Jean-Jacques Bienaimé said he would consider pursuing installment payment arrangements for the biotech’s experimental gene therapy for hemophilia. At the conference, Mr. Bienaimé told the Wall Street Journal that the one-time infusion, Valrox, is likely to cost in the millions because studies have shown it can eliminate bleeding episodes in patients, and current hemophilia treatments taken chronically can cost millions over several years. “We’re not trying to charge more than existing therapies,” he said. “We want to offer a better treatment at the same or lower cost.”

Johnson & Johnson Warns on Pricing

As politicians hammer drug prices, Johnson & Johnson CEO Alex Gorsky suggested companies need to police themselves. At the conference, Mr. Gorsky told investors that drug companies should price drugs reasonably and be transparent. “If we don’t do this as an industry, I think there will be other alternatives that will be more onerous for us,” Mr. Gorsky says. Some drugmakers pulled back from price increases in mid-2018 amid heightened political scrutiny, but prices went up for many drugs at the start of 2019.

Marijuana-Derived Drugs Show Promise

 

CVS Discusses New Stores

CVS Health Corp. Chief Executive Larry Merlo began showing initial concepts the company will be testing as it begins piloting new models of its drugstores that incorporate its Aetna combination. The first new test store will open next month in Houston, he told investors, and it will include expanded health-care services including a new concierge who will help patients with questions. 

Aetna Savings On the Way

Mr. Merlo also spelled out when the company will achieve the initial $750 million in synergies it has promised from the CVS-Aetna deal. In the first quarter, he said the company will see benefits from consolidating corporate functions. Savings from procurement and aligning lists of covered drugs should be seen in the first half, he says. Medical-cost savings will start affecting results toward the end of the year, he noted. 

Lilly Cuts Price

Drugmaker Eli Lilly & Co. expects average net US pricing for its drugs–after rebates and discounts–to decline in the low- to mid-single digits on a percentage basis this year, Chief Financial Officer Josh Smiley told the Journal. Lilly’s net prices had risen during the first half of 2018, but dropped in the third quarter as the company took a “restrained approach,” Mr. Smiley said. Lilly, which hasn’t yet reported fourth-quarter results, took some list price increases for cancer drugs in late December but hasn’t raised prices in the new year, he said.

Peter Loftus at peter.loftus@wsj.com and Anna Wilde Mathews at anna.mathews@wsj.com

Posted in Health Care System by Country, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment, Uncategorized, Value-based Drug Pricing | Tagged , , , , | Leave a Comment »

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 10, 2019: Deals and Announcements

January 10, 2019 by sjwilliamspa

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 10, 2019: Deals and Announcements

Reporter: Stephen J. Williams, Ph.D.

From Biospace.com

 

JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies

Published: Jan 10, 2019 By Alex Keown

Speaker presenting to audience at a conference

With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.

SAGE Therapeutics – Following a positive Phase III report that its postpartum depression treatment candidate SAGE-217 hit the mark in its late-stage clinical trial, Sage Therapeutics is eying the potential to have multiple treatment options available for patients. At the start of J.P. Morgan, Sage said that patients treated with SAGE-217 had a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression, compared to 13.6 for placebo. The company plans to seek approval for SAGE-2017, but before that, the FDA is expected to make a decision on Zulresso in March. Zulresso already passed muster from advisory committees in November, and if approved, would be the first drug specifically for postpartum depression. In an interview with the Business Journal, Chief Business Officer Mike Cloonan said the company believes there is room in the market for both medications, particularly since the medications address different patient populations.

 

Mersana Therapeutics – After a breakup with Takeda Pharmaceutical and the shelving of its lead product, Cambridge, Mass.-based Mersana is making a new path. Even though a partial clinical hold was lifted following the death of a patient the company opted to shelve development of XMT-1522. During a presentation at JPM, CEO Anna Protopapas noted that many other companies are developing therapies that target the HER2 protein, which led to the decision, according to the Boston Business Journal. Protopapas said the HER2 space is highly competitive and now the company will focus on its other asset, XMT-1536, an ADC targeting NaPi2b, an antigen highly expressed in the majority of non-squamous NSCLC and epithelial ovarian cancer. XMT-1536 is currently in Phase 1 clinical trials for NaPi2b-expressing cancers, including ovarian cancer, non-small cell lung cancer and other cancers. Data on XMT-1536 is expected in the first half of 2019.

Novavax – During a JPM presentation, Stan Erck, CEO of Novavax, pointed to the company’s RSV vaccine, which is in late-stage development. The vaccine is being developed for the mother, in order to protect an infant. The mother transfers the antibodies to the infant, which will provide the baby with protection from RSV in its first six months. Erck called the program historic. He said the Phase III program is in its fourth year and the company has vaccinated 4,636 women. He said they are tracking the women and the babies. Researchers call the mothers every week through the first six months of the baby’s life to acquire data. Erck said the company anticipates announcing trial data this quarter. If approved, Erck said the market for the vaccine could be a significant revenue driver.

“You have 3.9 million birth cohorts and we expect 80 percent to 90 percent of those mothers to be vaccinated as a pediatric vaccine and in the U.S. the market rate is somewhere between $750 million and a $1 billion and then double that for worldwide market. So it’s a large market and we will be first to market in this,” Erck said, according to a transcript of the presentation.

Denali Therapeutics – Denali forged a collaboration with Germany-based SIRION Biotech to develop gene therapies for central nervous disorders. The two companies plan to develop adeno-associated virus (AAV) vectors to enable therapeutics to cross the blood-brain barrier for clinical applications in neurodegenerative diseases including Parkinson’s, Alzheimer’s disease, ALS and certain other diseases of the CNS.

AstraZeneca – Pharma giant AstraZeneca reported that in 2019 net prices on average across the portfolio will decrease versus 2018. With a backdrop of intense public and government scrutiny over pricing, Market Access head Rick Suarez said the company is increasing its pricing transparency. Additionally, he said the company is looking at new ways to price drugs, such as value-based reimbursement agreements with payers, Pink Sheet reported.

Amarin Corporation – As the company eyes a potential label expansion approval for its cardiovascular disease treatment Vascepa, Amarin Corporation has been proactively hiring hundreds of sales reps. In the fourth quarter, the company hired 265 new sales reps, giving the company a sales team of more than 400, CEO John Thero said. Thero noted that is a label expansion is granted by the FDA, “revenues will increase at least 50 percent over what we did in the prior year, which would give us revenues of approximate $350 million in 2019.”

Government Woes – As the partial government shutdown in the United States continues into its third week, biotech leaders at JPM raised concern as the FDA’s carryover funds are dwindling. With no new funding coming in, reviews of New Drug Applications won’t be able to continue past February, Pink Sheet said. While reviews are currently ongoing, no New Drug Applications are being accepted by the FDA at this time. With the halt of NDA applications, that has also caused some companies to delay plans for an initial public offering. It’s hard to raise potential investor excitement without the regulatory support of a potential drug approval. During a panel discussion, Jonathan Leff, a partner at Deerfield Management, noted that the ongoing government shutdown is a reminder of how “overwhelmingly dependent the whole industry of biotech and drug development is on government,” Pink Sheet said.

Other posts on the JP Morgan 2019 Healthcare Conference on this Open Access Journal include:

#JPM19 Conference: Lilly Announces Agreement To Acquire Loxo Oncology

36th Annual J.P. Morgan HEALTHCARE CONFERENCE January 8 – 11, 2018

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: #JPM2019 for Jan. 8, 2019; Opening Videos, Novartis expands Cell Therapies, January 7 – 10, 2019, Westin St. Francis Hotel | San Francisco, California

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 8, 2019: Deals and Announcements

 

Posted in BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Curation, Drug Development Process, FDA, FDA Regulatory Affairs, Genetics & Pharmaceutical, Molecular Genetics & Pharmaceutical, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment, Precision Cancer Medicine, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, Transformative Technologies in Healthcare, Translational Science, Venture Capital | Tagged , , , , , , , , , , , , , , | Leave a Comment »

The Value of a Pre-mortem Session with the Management Team

January 10, 2019 by

The Value of a Pre-mortem Session with the Management Team

Author: Amnon Danzig,

LPBI Group, Business Development Team

 

What is the Value of a Pre-mortem Session with the Management Team?

When an executive thinks about innovation and growth strategies he/she should hedge themselves against potential failures. One of the recommended tools for it is a Pre-mortem Session with the Management Team.

A Pre-mortem Session with the Management Team is a tool that utilizes the prospective hindsight concept. Prospective Hindsight is an approach to “look forward by looking backward.” One assumes that you have already reached the point of a few years from the Present, and tries to figure out why certain events and processes had took place.  

A Pre-mortem Session with the Management Team is analogous to a human postmortem analysis. In medicine, postmortem is used by medical doctors to understand why they failed after the patient passes away.

Gary Klein (“Performing a Project Premortem”, HBR September 01, 2007) took the postmortem concept one step further and adapted it to managerial situations, hence the Pre-mortem methodology for business management had emerged. Daniel Kahneman (Thinking, Fast and Slow, 2011) made this analytical approach more popular due to its inclusion in his last book .

 

My personal version of A Pre-mortem Session with the Management Team is the following: 
After you finalize your project plan, and everything is ready for kick-off, gather your management team and all the core people that were part of the development of the company’s knowledge base of the project under analysis.

  • Suggested is a Friday evening, just one hour before the end of the workday.
  • Clear all mobile devices: laptops and smart phones
  • Distribute beer,
  • supply a sheet paper and pencils

Here is your pitch:
“Ladies and gentlemen, today is a date three years into the future. You announce that the project has failed. Furthermore, it puts our company at risk. Period.

  • Now you have a budget of seven minutes and one bottle of beer.

In full voice you tell the Team, please, write the chronology of this failure; all the things that caused this dramatic failure. Let’s start.”

  • After seven minutes, gather the papers and thank the participants.

You then take the papers and read them carefully at home. Read and reread until you fully grasp  all the new insights your colleagues have shared with you.
At a glance, this process encapsulates the entire body of knowledge of the project’s shortcomings and drawbacks:

  • You pose and ask: what are the causes of this dramatic failure?

Next Monday morning, you gather the same group: sheet of papers and pencils for each participant. No beer…
You ask them to articulate the project evolution, taking into account what they wrote on Friday evening. Give them one hour. Collect the papers and thank them.

Now you have a fine springboard to re-examine the project. What is the reason to do that?

  • It is pretty simple: while preparing new projects under your strong leadership, all the doubts, critics, annoying facts and unpopular standpoints are moved to the side.
  • Your team can develop group thinking, which is could be very risky while preparing the knowledge base for the new project.
  • In a Pre-mortem session with the Team, you facilitate even negativism about the project, or parts of it.

Daniel Kahneman said in few lectures that executives find this extremely beneficial to them.

Posted in BioTechnology - Venture Creation | Leave a Comment »

2019 Trends in Precision Medicine: A Perspective from Foundation Medicine

January 9, 2019 by 2012pharmaceutical

2019 Trends in Precision Medicine: A Perspective from Foundation Medicine

Reporter: Aviva Lev-Ari, PhD, RN

 

BIOPHARMA, DIAGNOSTICS

Foundation Medicine appoints new CEO; exec provides forecasts for precision medicine in 2019

With the approval of Loxo’s Vitrakvi, pan-cancer drugs and an emphasis on real-world data are likely to become important trends trends this year.

By ALARIC DEARMENT

 Jan 8, 2019 at 6:17 PM

A next-generation sequencing firm that last year became wholly owned by Swiss drugmaker Roche has appointed a new leader.

Cambridge, Massachusetts-based Foundation Medicine said Monday that it had appointed Cindy Perettie as CEO, effective Feb. 4. Succeeding Troy Cox, Perettie was most recently senior vice president for global oncology product strategy at Roche’s oncology unit. She previously had begun working for Genentech in 2004 and continued working there through that company’s 2009 acquisition by Roche, before moving to the Sarah Cannon Research Institute as president for global development innovations.

Foundation Medicine markets genomic sequencing products for use in oncology, including in next-generation sequencing for solid and hematological cancers and liquid biopsy. Roche, which was already a majority shareholder in the company, bought the rest of it in June for $2.4 billion.

The Roche acquisition and new executive appointment have come at a time when genomic sequencing has become a crucial component of precision medicine.

In an interview at the J.P. Morgan Healthcare Conference in San Francisco, Chief Business Officer Melanie Nallicheri did not comment on Perettie’s appointment, but discussed some of her expectations for what 2019 has in store for precision medicine.

In particular, she said the November approval of Loxo Oncology and Bayer’s Vitrakvi (larotrectinib) is a taste of things to come. “This is the second pan-cancer approval,” she said. “So the notion of really moving away from cancer as a tissue disease to cancer as a genomic disease, we’re starting to see that take hold.

Loxo has a partnership with Illumina to develop a companion diagnostic for Vitrakvi, though Nallicheri noted that Foundation Medicine works with the company as well. Eli Lilly & Co. said Monday it would acquire Loxo for $8 billion.

When there was only one such approval, namely for Merck & Co.’s Keytruda (pembrolizumab) in microsatellite instability-high and mismatch repair-deficiency cancers in 2017, it may have been possible to say that was a one-off, she said. But Vitrakvi’s approval changes that. Yet, even the Keytruda approval may be predictive. Quantitative biomarkers like MSI-H and tumor mutational burden can support approval, so that’s probably an important trend of which more will be seen.

Another area in which Nallicheri said Foundation Medicine can have a role is in providing real-world clinical data, which she said is also likely to become an important trend in 2019, particularly given the guidance from the Food and Drug Administration. A guidance released last month outlined a new framework for advancing real-world evidence to support drug and biologic development. In addition, in a breakout session at JPM Tuesday, executives from Roche emphasized the potential for historical data to serve as a synthetic control arm, pointing to the Swiss drugmaker’s $1.9 billion acquisition of Flatiron Health in February 2018. “The idea that you can replace control arms with historical data is tangible,” Roche CEO Severin Schwan said in the session. “This is not just a hypothesis – it’s real life.”

SOURCE

https://medcitynews.com/2019/01/foundation-medicine-appoints-new-ceo-exec-provides-forecasts-for-precision-medicine-in-2019/?rf=1

 

Other related articles published on this Open Access Online Scientific Journal include the following:

#JPM19 Conference: Lilly Announces Agreement To Acquire Loxo Oncology

PMC Strategic Plan for 2019

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: #JPM2019 for Jan. 8, 2019; Opening Videos, Novartis expands Cell Therapies, January 7 – 10, 2019, Westin St. Francis Hotel | San Francisco, California

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 8, 2019: Deals and Announcements

 

Series B: Frontiers in Genomics Research

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

https://read.amazon.com/kp/card?preview=inline&linkCode=kpd&ref_=k4w_oembed_LQjKhQ55I5i8WS&asin=B018DHBUO6&tag=kpembed-20
  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Work-in-Progress

 

Posted in Personalized and Precision Medicine & Genomic Research | Leave a Comment »

« Newer Posts - Older Posts »